Kornimate/medical-research-clean huggingface dataset:
bladder cancer detection using convolutional neural networks

Conditions: Bladder Cancer

Summary: the investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in computer-aided diagnosis (cad) systems. in particular, the investigators are interested in detecting bladder tumors from ct urography scans and cystoscopies of the bladder in this project.

the investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in computer-aided diagnosis (cad) systems. in particular, the investigators are interested in detecting bladder tumors from ct urography scans and cystoscopies of the bladder in this project. the investigators want to classify bladder tumors as cancer, non cancer, high grade and low grade, invasive and non-invasive, with high sensitivity and low false positive rate using various convolutional neural networks (cnn). this task can be considered as the first step in building cad systems for bladder cancer diagnosis. moreover, by automating this task, the investigator scan significantly reduce the time for the radiologists to create large-scale labeled datasets of ct-urography scans and reduce the false-negative and positive that can happen due to human evaluation cystoscopies.

Eligibility criteria:
inclusion criteria: * patients with first time hematuria * patients with the control program for previous bladder cancer exclusion criteria: * patients with control cystoscope for noncancer suspected disease

Keywords: machine learning artificial intelligence
prehospital evaluation and economic analysis of different coronary syndrome treatment strategies - predict

Conditions: Myocardial Ischemia; Myocardial Infarction

Summary: despite remarkable gains in treatment over the last decade short-term mortality for those who survive to hospital with at-elevation acute myocardial infarction (stemi) remains high (5%-10%). different studies have pointed out that reperfusion (intravenous fibrinolysis or percutaneous coronary interventions (pci) and its timing are critical in decreasing stemi patients' mortality. studies of prehospital 12 lead electrocardiograms (12 lead phecg) with advance emergency department (ed) notification suggest that there is a time to treatment advantage with this intervention. the use of 12 lead phecg is not currently universal and part of standard treatment throughout the province. the purpose of the study is to follow stemi study subjects during standard treatments and to compare the outcomes of subjects that received 12 lead phecg with advanced ed notification in mixed rural/urban areas with outcomes of subjects treated in areas with only 3 lead phecg monitoring and indirect ed notification. the investigators hypothesize that there will be a survival benefit for study subjects with 12 lead phecg and advance ed notification in rural and urban environments through a reduction in door-to-reperfusion time and that 12 lead phecg will be a cost-saving technology for the province of ontario.

many studies have established that reperfusion reduces mortality in st-elevation acute myocardial infarction (stemi) patients; the earlier reperfusion therapy is delivered, the greater the mortality reduction. most stemi patient in ontario still do not receive reperfusion therapy within established target times of \<30 minutes for fibrinolysis or \<90 minutes for pci. 12 lead phecg with advance ed notification may have a time to treatment impact in stemi patients. however studies, investigating this intervention were all small, largely urban trials, and were carried out with advanced care paramedics. in ontario, many emergency medical services (ems) systems cover large rural regions, and are frequently staffed by primary care paramedics with only basic life support training. thus, the benefit of 12 lead phecg in these settings is unclear. in addition, no study has assessed the cost-effectiveness of 12 lead phecg compared to 3 lead phecg.

Eligibility criteria:
inclusion criteria: * call 911 for assistance * are suspected by the paramedics of having ischemic chest pain for greater than 30 minutes but less than 6 hours * be greater than or equal to 18 years of age * experience chest pain that fails to completely respond to nitrates as per standard provincial chest pain protocol. exclusion criteria: * subjects less than 18 years of age

Keywords: electrocardiography emergency medical services emergency medicine health services cost effectiveness
oncological and functional outcomes after radical prostatectomy for prostate cancer: comparing open with robot-assisted surgery

Conditions: Prostate Cancer

Summary: for primary surgical treatment of prostate cancer the investigators compare the classic open surgery (radical retropubic prostatectomy, rrp) versus robot-assisted laparoscopic surgery (ralp). oncological results are obtained at standard follow-up consultations through prostate-specific antigen (psa) measurement to detect biochemical recurrence. functional results (continence, potency, quality of life) are obtained through standardised questionnaires. currently the investigators perform all of their prostatectomies in a robot-assisted manner. for results of the open surgery the investigators send questionnaires to patients who had the operation in the past.


Eligibility criteria:
inclusion criteria: * prostate cancer * radical retropubic prostatectomy or * robot-assisted laparoscopic surgery exclusion criteria: -

Keywords: prostate cancer
efficacy and tolerance of ultrasound-guided needling and lavage of calcific tendinitis of the rotator cuff performed with or without subacromial corticosteroid injection

Conditions: Calcifying Tendinitis of Shoulder

Summary: calcific tendinitis of the rotator cuff is a common cause of chronic pain of the shoulder. needling and lavage of the calcification is one of the therapeutic options after failure of conservative management with physiotherapy and anti-inflammatory drugs. needling is usually followed by a corticosteroid injection in the subacromial bursae in order to prevent acute pain reaction due to the intervention. however, the relevance of this injection has never been proven. moreover, corticosteroid could prevent the inflammatory reaction induced by the needling and thus the body's natural calcium resorption processes. finally, corticosteroids could have deleterious effect on the tendon structures and favour local infection. our hypothesis is that corticosteroid have no significant effect on acute pain after needling and therefore should not been performed systematically after needling.


Eligibility criteria:
inclusion criteria: * shoulder pain for at least 3 month * positive hawkins, yocum and/or neer test for impingement * calcific deposit \>= 5 mm on shoulder x-ray in one the tendon of the rotator cuff exclusion criteria: * allergy to lidocaïne or methylprednisolone acetate * acute pain suggestive of resorption of the calcification with ill-defined - calcification on x-ray * other shoulder diseases : ostearthritis of the gleno-humeral or acromio-clavicular joint * sonographic findings of rotator cuff tear * subacromial steroid injection in the previous month * uncontrolled diabetes * pregnant women * contraindication for the use of nonsteroidal antiinflammatory drugs or paracetamol/acetaminophene

Keywords: calcifying tendinitis needle lavage shoulder corticosteroid injection ultrasound-guided
rekindle: registry with enbrel® or kineret® in a database using longitudinal evaluations

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine if enbrel® or kineret® will have a positive effect on subject functionality as measured by the health assessment questionnaire disability index (haqdi).


Eligibility criteria:
inclusion criteria: - subjects with active rheumatoid arthritis as defined by acr criteria - able to start enbrel® or kineret® therapy (per the approved product monographs) within approximately 30 days of confirmed enrolment exclusion criteria: - active infections at the time of initiating enbrel® or kineret® therapy - malignancy other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years - known hypersensitivity to e. coli derived products - known hypersensitivity to enbrel® or any of its components - subjects receiving, or who received:\* enbrel® in the previous 30 days; \* remicade® in the previous 3 months; \* humira® in the previous 3 months; \* kineret® in the previous 15 days. - subjects beginning enbrel® therapy, or treated with prior or current treatment using enbrel® - subjects beginning kineret® therapy, or treated with prior or current treatment using kineret® - treatment with any investigational therapy in the 30 days prior to enrolment confirmation - presence of any significant and uncontrolled medical condition which, in the investigator's opinion, precludes the use of enbrel® - sepsis or at risk of septic syndrome
a study to determine the safety and tolerability of dupilumab (regn668/sar231893) in patients aged ≥6 to <18 years with atopic dermatitis (eczema)

Conditions: Atopic Dermatitis

Summary: the primary objective of the study is to characterize the safety and pharmacokinetics (pk) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (ad) (for adolescents ≥12 to \<18 years of age) or severe ad (for children ≥6 to \<12 years of age). the secondary objective of the study is to explore the immunogenicity and efficacy of dupilumab in pediatric patients with moderate-to-severe ad (for adolescents ≥12 to \<18 years of age) or severe ad (for children ≥6 to \<12 years of age).


Eligibility criteria:
key inclusion criteria: 1. male or female patients ≥6 to \<18 years of age with a diagnosis of 1. atopic dermatitis whose disease cannot be adequately controlled with topical medications 2. minimum disease severity, as defined by investigator's global assessment (iga) 1. iga = 3 or 4 in adolescents ≥12 to \<18 year of age 2. iga = 4 in children ≥6 to \<12 years of age key exclusion criteria: 1. recent treatment (within specific time windows before the baseline visit) with systemic immunosuppressive agents for eg. systemic corticosteroids, live (attenuated) vaccines and other investigational drugs including biologics 2. history of any of the following infections: 1. any systemic infection requiring treatment within 4 weeks before the baseline visit 2. superficial skin infections within 1 week before the baseline visit 3. known history of hiv infection 4. history of seropositivity to hepatitis b or c screening tests 5. history of clinical endoparasitosis (ie, helminthic infection) within 12 months before the baseline visit, or high risk of helminthic infection, unless subsequent medical assessments (e.g. stool exam, blood tests, etc.) have ruled out the possibility of parasite infection/infestation 3. history of malignancy within 5 years before the baseline visit 4. persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases (alanine aminotransferase \[alt\] and/or aspartate aminotransferase \[ast\]) more than 3 times the upper limit of normal (uln) during the screening period 5. presence of any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study 6. presence of skin comorbidities that may interfere with study assessments 7. females patients who are pregnant or breastfeeding 8. female patients who are of reproductive potential and are sexually active, who are unwilling to use adequate methods of contraception

Keywords: eczema
synchronization of ovarian stimulation for in vitro fertilization with follicular wave emergence

Conditions: Infertility

Summary: ovarian stimulation is an important phase of in vitro fertilization (ivf) treatments. the harvest of a larger number of viable eggs per cycle compensate eventual laboratory difficulties and allow for the selection of embryos with higher implantation potential. in the current protocols, based on the most prevailing theory of ovarian follicular development, stimulation drugs are usually started on the second or third day after the beginning of menses. the follicular phase of the menstrual cycle is believed to be the only favorable moment for follicular development. in the early 2000's a new model of human ovarian follicular development (follicular waves) has been proposed based on frequent transvaginal ultrasound observations between two ovulations. it has been shown that ovarian antral follicles develop in synchronous groups, two to three times in a cycle. in fact the follicular wave phenomenon has been initially described in the 80's on domestic animals, like the mare and the cow. moreover, studies in these animals have shown that synchronizing the start of the ovarian stimulation drugs with the beginning of a follicular wave yields better results for assisted reproductive treatments. consequently in ovarian stimulation protocols for animal assisted reproduction it is important to control the initiation of a follicular wave. current protocols of ovarian stimulation for ivf in women do not consider the start of a follicular wave to begin drug administration. therefore the purpose of this study is to evaluate two methods to control the emergence of a follicular wave (ovulation induction and dominant follicle aspiration) and to investigate the effects of synchronizing ovarian stimulation for ivf with follicular wave emergence in women compared to one of the current stimulation protocols (flexible gnrh protocol).


Eligibility criteria:
inclusion criteria: * age \< 35 years old * body mass index: 19-30 kg/m2 * tubal or male factor infertility with indication of in vitro fertilization * antral follicle count: 10-20 * normal uterus in transvaginal ultrasound scan * fsh on the third day of the menstrual cycle below 12mui/ml and estradiol below 80pg/ml * male partner with at least 5 million motile sperm and 1% normal strict morphology on semen analyses exclusion criteria: * ovarian factor infertility * non identification of one or both ovaries in the transvaginal ultrasound scan * non treated endocrine disorders * smoking habit * endometriosis stage iii -iv * severe male factor infertility (less than one million sperm per ml of semen)

Keywords: in vitro fertilization ovarian stimulation follicular waves luteal phase
do treatments for smoking cessation affect alcohol drinking? study 1: nicotine replacement therapy

Conditions: Alcohol Drinking

Summary: this study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.


Eligibility criteria:
inclusion criteria: * ages 21 and over * able to read and write in english * smoker * heavy drinker exclusion criteria: * any significant current medical or psychiatric conditions that would contraindicate the consumption of alcohol or nicotine * significant hepatocellular injury * positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines * women who are pregnant or nursing * suicidal, homicidal, or evidence of severe mental illness * prescription of any psychotropic drug in the 30 days prior to study enrollment * blood donation within the past 8 weeks * individuals who are seeking treatment for drinking or smoking who have attempted to quit drinking or smoking within the past 3 months * specific exclusions for administration of nicotine nasal spray not specified above including nasal polyps, chronic nasal congestion, allergies, sinusitis * specific exclusions for administration of nicotine patch not specified above including history of dermatoses * reported sensitivity or allergies to pepper or pepper spray, peppermint, or prior adverse reaction to nicotine spray * participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current study

Keywords: alcohol nicotine smoking cessation smoking cessation medications
prospective descriptive study of the angiogenic t cell population in subjects with hereditary hemorrhagic telangiectasia (hht)

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: hereditary hemorrhagic telangiectasia (hht) results from genetic deregulation of angiogenesis. it is characterized by mucocutaneous telangiectasia responsible for recurrent epistaxis affecting quality of life (anaemia, iron deficiency, social distress). more rarely, hht is complicated by the appearance of pulmonary, hepatic or cerebral arteriovenous malformations that can lead to serious complications: cerebrovascular accidents, cerebral abscesses, high output heart failure, and massive hemoptysis (1). the intensity of symptoms increases with age but with significant individual variability, even for the same mutation in the same family. thus, while the mutations responsible for the disease have been identified, the pathophysiology is not fully understood because these mutations do not explain the great diversity of clinical presentations. other factors not yet identified probably play an important role. angiogenic t cells (tang) are a newly individualized t cell population, defined by a cd4+cxcr4+cd31+ phenotype, which plays a key role in differentiating endothelial progenitors (2). in an earlier study, the investigators showed that patients with hht had a decrease in cd4+ and cd8+ lt compared to a cohort of healthy subjects (3). they hypothesize that the lymphopenia mainly involves tang, whose quantification could make it possible to assess the individual level of angiogenesis during hht. the evaluation of the tang levels could thus make it possible to personalize hht management.


Eligibility criteria:
inclusion criteria: * person who has given consent * adult * person capable of understanding spoken and written french "patient" group: * certain hht (3 or 4 curacao criteria - appendix 2): * recurring epistaxis * telangiectasia of the skin or mouth * family hereditary context * arteriovenous visceral malformations * causal mutation identified * person capable of completing monthly epistaxis charts "control" group : - control subjects will be matched to patients for age (+/- 6 years) and sex. exclusion criteria: * person not affiliated to a national health insurance scheme * pregnant or breastfeeding woman * protected adult * hemoglobin levels less than 9 g/dl in the last 15 days * progressive or recent infectious disease, autoimmune disease or cancer (less than 6 months) * immunosuppressive treatment in progress or recent (less than 6 months), including systemic steroid therapy. the use of inhaled or topical steroids is not an exclusion criterion. * treatment in progress or stopped less than 6 months ago or to be introduced within the next 3 months of the following medications: * bevacizumab * tranexamic acid * dipeptidyl peptidase 4 inhibitors (diabetic patient) * beta-blockers (hypertensive patient)
pregabalin vs placebo in treatment of neuropathic pain associated with diabetic peripheral neuropathy

Conditions: Diabetic Neuropathies

Summary: to evaluate the efficacy and safety of pregabalin administered twice a day compared to placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.


Eligibility criteria:
inclusion criteria: * males or females at least 18 years of age, of any ethnic origin * type 1 or 2 diabetes mellitus * pain score greater than or equal to 4 on the 11-point numeric pain rating scale exclusion criteria: * neurologic disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain. * presence of severe pain associated with conditions other than diabetic peripheral neuropathy, that could confound the assessment or self-evaluation of pain due to dpn.
relationship between flexible flat foot and lumbar proprioception

Conditions: Flexible Flatfoot; Lumbar Spine Injury; Proprioceptive Disorders

Summary: the purpose of this study was to determine the relationship between flexible flatfoot and lumbar proprioception.

the human foot plays a crucial role in maintaining balance during various activities, and poor foot alignment, such as excessive subtalar joint pronation, can lead to leg, knee, and back pain. proprioception is essential for active joint stability, as it indirectly modulates and provides motor response, helping the neuromuscular system maintain balance. lumbar proprioception deficits can decrease the ability to assume a neutral spinal posture and coordinate muscle contraction, affecting spinal segmental function, dynamic joint stability, and good motor control. this study investigates the association between flatfoot and lumbar proprioception.

Eligibility criteria:
inclusion criteria: * 60 subjects of both sexes (females and males) were selected and assigned into two groups * patient's age range was between 17 to 30 years old. * subjects with flexible flat foot posture according to the navicular drop test by brody method: a normal foot (between five and nine mm of navicular drop), pronated foot (more than 10 mm of navicular drop). * patients will be willing and able to participate in assessment without cognitive impairments that would limit their participation exclusion criteria: the potential participation was excluded when they had one of the following criteria: * repeated lower extremity injuries, such as fractures or deformities. * history of surgery to the lower extremity. * history of back surgery * rheumatologic disorders * spine infections * ankle fracture * lumbar fracture * spondylosis * lumbar disc bulge * spondylolisthesis
multiple dose safety toelrability, pharmacokinetics and midazolam interaction in healthy overweight and obese subjects

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders

Summary: this study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of pf-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ecg and clinical laboratory tests). * body mass index (bmi) of 25 to 35 kg/m2 inclusive; and a total body weight \>50 kg (110 lbs). * subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * evidence or history of any chronic ongoing or current pulmonary disease. * history of smoking in the past 5 years and a history of smoking more than 10 pack years, or history or evidence of habitual use of other (non smoked) tobacco or nicotine containing products. active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms or retinal/optic nerve disease.